When the year ends it is a good time to look back and review the challenges achieved in the last twelve months. More than 1,300 scientific articles, of which 550 are led by IDIBELL, show that there many objectives have been achieved, but there are also many questions that remain to be answered.
We close a 2021 full of science! Read More »
A research group from IDIBELL has identified genes relevant to the oxidative stress response that could help design new treatments for cystic fibrosis.
Finding new paths in the treatment of cystic fibrosis Read More »
Two studies published in The New England Journal of Medicine, with the participation of IDIBELL and the ICO, present the results of two phase 3 clinical trials comparing treatment with CART lymphocytes versus conventional treatment with chemotherapy and bone marrow transplantation.
A team from IDIBELL, the Bellvitge University Hospital and CIBERSAM, in collaboration with ISGlobal and Harvard Medical School, have described alterations in two genes that would explain the abnormally reverberant behavior of the brain circuits involved in OCD.
The results of the study, published in the journal Advanced Science, show that reducing the expression of a group of microRNAs in fat tissue causes an increase in the number of fat-storing cells and their hypertrophic growth.
Researchers discover a new genetic regulation pathway associated with obesity Read More »
It reflects on the time spent playing, the stereotypes and values that video games can transmit
The Association of Women with Breast Cancer (DACMA) has donated a check for 8,000 euros to IDIBELl and ICO dedicated to breast cancer research. This donation counted on the participation of Belén García, the mayor of Sant Joan Despí, where DACMA has its headquarters, who wanted to accompany the entity members in this event.
The DACMA Association donates 8,000 euros for breast cancer research Read More »
The most innovative projects in the healthcare and biomedical sector were presented on December the 16th at the fourth edition of the Accelerator Meeting Point (AMP), organized by the Business Development and Innovation Area of the Biomedical Research Institute of Bellvitge (IDIBELL). The fourth edition of the AMP has counted on the participation of AIISEM,
The new trial allows human papilloma virus (HPV) detection and genotyping with the same sensitivity as other commonly used PCRs but following a much simpler procedure.
New diagnostic technique for HPV detection in oropharyngeal cancers Read More »
Un estudio del IDIBELL y el Hospital Universitario de Bellvitge ha descrito como las vacunas han cambiado la distribución de los distintos serotipos de neumococo.
Scientists describe how vaccination has affected bacterial variants that cause pneumonia Read More »
